Trial Profile
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Plocabulin (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Gastrointestinal stromal tumours; Germ cell and embryonal neoplasms; Germ cell cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions
- Sponsors PharmaMar
- 24 Oct 2023 Results reporting safety and efficacy data presented at the 48th European Society for Medical Oncology Congress
- 20 Apr 2021 Status changed from recruiting to completed.
- 03 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2019.